Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition

Jian Yin,¹ Peter Richard Sternes,² Mingbang Wang ,³ Jing Song,¹ Mark Morrison,⁴ Ting Li,¹ Ling Zhou,¹ Xin Wu,¹ Fusheng He,⁵ Jian Zhu ,⁶ Matthew A Brown ,² Huji Xu^{1,6,7}

Handling editor Josef S Smolen

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2019-215763>).

For numbered affiliations see end of article.

Correspondence to

Professor Matthew A Brown, Guy's & St Thomas' NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, Guy's Hospital, London, UK; matt.brown@qut.edu.au and Professor Huji Xu, Beijing Tsinghua Changgong Hospital School of Clinical Medicine Tsinghua University, Beijing 100084, China; huji_xu@tsinghua.edu.cn

JY and PRS contributed equally. MAB and HX contributed equally.

Received 22 May 2019
Revised 9 October 2019
Accepted 10 October 2019
Published Online First
29 October 2019

ABSTRACT

Objectives Diverse evidence including clinical, genetic and microbiome studies support a major role of the gut microbiome in the common immune-mediated arthropathy, ankylosing spondylitis (AS). We set out to (1) further define the key microbial characteristics driving disease, and (2) examine the effects of tumour necrosis factor-inhibitor (TNFi) therapy upon the microbiome.

Methods The stools from a case-control cohort of 250 Han-Chinese subjects underwent shotgun metagenomic sequencing. All subjects were genotyped using the Illumina CoreExome SNP microarray.

Results Previous reports of gut dysbiosis in AS were reconfirmed and several notable bacterial species and functional categories were differentially abundant. TNFi therapy was correlated with a restoration the perturbed microbiome observed in untreated AS cases to that of healthy controls, including several important bacterial species that have been previously associated with AS and other related diseases. Enrichment of bacterial peptides homologous to HLA-B27-presented epitopes was observed in the stools of patients with AS, suggesting that either HLA-B27 fails to clear these or that they are involved in driving HLA-B27-associated immune reactions. TNFi therapy largely restored the perturbed microbiome observed in untreated AS cases to that of healthy controls, including several important bacterial species that have been previously associated with AS and other related diseases. TNFi therapy of patients with AS was also associated with a reduction of potentially arthritogenic bacterial peptides, relative to untreated patients.

Conclusion These findings emphasise the key role that the gut microbiome plays in driving the pathogenesis of AS and highlight potential therapeutic and/or preventative targets.

Key messages

What is already known about this subject?

- Clinical, genetic and microbiome evidence supports the contention that ankylosing spondylitis (AS) is influenced by interactions between the gut microbiome and the host immune system.
- The majority of microbiome studies to date have been conducted via sequencing of the 16S ribosomal marker gene, limiting the scope and accuracy of downstream analytics.

What does this study add?

- This study contributes three major findings in regards to the role of the gut microbiome in AS: (1) the AS gut microbiome is shaped such that cases carry a higher load of peptides known to be presented by HLA-B27. (2) Changes in prevalence of clinically relevant bacterial species and metabolic pathways that are known to be conducive for proinflammatory responses were noted, and (3) tumour necrosis factor-inhibitor (TNFi) therapy was correlated with restoration of the perturbed microbiome, highlighting a potential mechanism of action for these drugs.

How might this impact on clinical practice or future developments?

- Therapeutic and/or preventative modulation of the gut microbiome remains an attractive strategy. To achieve this, precise identification of the microbial characteristics potentially driving disease is required.

INTRODUCTION

Ankylosing spondylitis (AS) has been shown in both twin and unrelated case/control studies to be highly heritable (twins >90% heritability).^{1,2} There is substantial evidence suggesting that the interaction between host genetics and gut microbiome is a key driver of the pathogenesis of AS. The high disease heritability indicates that the environmental factors involved in the disease are likely to be ubiquitous.

Reactive arthritis is a spondyloarthritis (SpA) sharing many clinical and genetic features with AS and is known to be caused by bacterial infections of the gut or urinary tract; a subset of patients with reactive arthritis go on to develop AS. About 60% patients with AS suffered from subclinical bowel inflammation and 10% of them can be diagnosed as inflammatory bowel disease (IBD).³ There is considerable overlap in the overall heritability of AS and IBD,⁴ the two diseases are often cofamilial⁵

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Yin J, Sternes PR, Wang M, et al. *Ann Rheum Dis* 2020;**79**:132–140.

and many shared genetic associations have been identified.⁶ A bioinformatic study showed that AS susceptibility genes specifically enriched in gut cells are also enriched in 'response to bacterium' GO term pathway and that AS-associated genetic loci are found disproportionately to lie within epigenetic marks of gene activity in gut tissue and cells.⁷ Germ-free *HLA-B27*-transgenic rats and SKG mice are disease-free.^{8,9} Studies using sequencing-based bacterial profiling of terminal ileal biopsies showed that patients with AS have a distinct microbiome,¹⁰ a finding that has subsequently been reproduced studying stool samples in patients with AS and patients with SpA, a broader clinical classification.¹¹ Recently, *HLA-B27*-positive healthy individuals were shown have a significantly different microbiome, indicating that the gut microbiome may in fact be a driver of AS, as opposed to being secondary to it.¹² There has also been suggestive evidence reported that the gut microbiome is associated with differences in AS disease activity.¹³ In addition, one study compared stool samples of patients with SpA before and 3 months after the tumor necrosis factor-inhibitor (TNFi) treatment onset.¹⁴ Although modest changes were found in microbiome alpha-diversity measures after TNFi treatment, no changes in specific bacterial taxa were observed. In summation, the above evidence supports the contention that AS status is influenced by interactions between the gut microbiome and the host immune system.

To date, the mechanisms involved in the interaction between the host immune system and intestinal microbes remain unclear. One hypothesis suggests that *HLA-B27* presents specific peptides to CD8+T cells, leading to pathogenic adaptive immune responses (the 'arthritogenic peptide theory'). The gut microbiota produces a huge variety and number of peptides, and as such, microbial peptides intrinsic to dysbiosis may activate CD8+T cells. In that context, Purcell and colleagues identified 7500 such peptides that bind the eight most common *HLA-B27* subtypes.¹⁵ Here, we present our findings from a shotgun metagenomics sequencing study undertaken with stool samples collected from 250 Chinese individuals to investigate evidence of dysbiosis in AS, the effect of TNFi treatment on the gut microbiota and to investigate evidence of immunity to *HLA-B27*-restricted microbial peptides in AS cases.

MATERIALS AND METHODS

Subject recruitment

A total of 127 unrelated Han Chinese AS cases meeting the 1984 modified New York criteria for AS¹⁶ were recruited from the Department of Rheumatology and Immunology of Shanghai Changzheng Hospital (Shanghai, China). A total of 123 healthy controls (blood donors on no prescription medications) were recruited from Shanghai. All human studies have been approved by the Research Ethical Committee of Second Military Medical University, and all patients and controls gave informed written consent for their participation in the studies. Clinical and dietary information was collected described in the online supplementary methods.

Shotgun metagenome sequencing

DNA extracted from faecal samples were extracted and sequenced using an Illumina HiSeq sequencer (Illumina, San Diego, California, USA) with the paired-end 150 bp sequencing model based on >5G raw data output per sample (see the online supplementary material for more detail).

Manual inspection and QC of sequencing reads were conducted using FastQC v10.1.¹⁷ Paired-end reads were joined using PEAR v0.9.10¹⁸ and adapters were trimmed using

Trimmomatic v0.36.¹⁹ Contaminant sequences, such as those mapping to human or PhiX genomes, were filtered using Bowtie2 v2.3.4²⁰ and the remaining reads were counted and subsampled to an equal sequencing depth of 3 520 000 sequencing reads per sample using SeqTK v1.0.²¹ MetaPhlAn2 v2.6.0²² was used for taxonomic classification, PanPhlAn v1.2.2²³ was used for strain-level profiling using precomputed pan-genome references where possible, and HUMAnN2 v0.11.1²⁴ was used for functional mapping to KEGG Orthogroups (KO) and MetaCyc pathways and using a UniRef90 database.

For the prediction of bacterial peptides homologous to previously reported *HLA-B27*-presented epitopes, all available bacterial-derived sequencing reads were BLASTXed against a local, BLAST-formatted,²⁵ version of the immune epitope database (IEDB) v3.0 (downloaded August 2016).^{26,27} BLAST best-hits with an E-value <0.1, as well as their corresponding IEDB annotations, were collected and counted. The analysed version of IEDB contained 7500 peptides which were previously identified as *HLA-B27*-presented via proteomics.¹⁵ The abundance of each *HLA-B27*-presented peptide in cases vs controls was evaluated by Wilcoxon rank-sum testing (false discovery rate (FDR) corrected) and the presence/absence of the peptides in cases vs controls was evaluated via the Fisher exact test (FDR corrected), with $Q < 0.05$ considered significant.

Further microbiome analyses were performed using R as outlined in the online supplementary methods.

T-cell responses to microbiome-derived peptides

Individual peptides, previously shown to be presented by *HLA-B27* and found in AS case stool microbiomes, were used to pulse peripheral blood mononuclear cells (PBMCs) from either *HLA-B27*-positive or *HLA-B27*-negative donors. Pulsed PBMCs were cocultured with autologous PBMC in T-RF10+interleukin-2 (10 U/mL). On day 20 of culture, cells were restimulated with peptide-pulsed irradiated autologous lymphoblastoid cells, and CD4 T cells depleted by magnetic sorting. Ten to 14 days later, interferon-gamma (IFN- γ) production by CD8 T cells was determined by intracellular cytokine staining. Two runs were performed, each run involving different peptides, for both the *HLA-B27*-positive and *HLA-B27*-negative donors.

RESULTS

Gut dysbiosis in AS

The case and control cohorts were divided into discovery and validation cohorts prior to analysis; the discovery cohort consisted of 97 AS cases and 93 healthy controls with age-matched demographics, and the remaining 60 subjects comprised the validation cohort (30 AS cases and 30 healthy controls) (online supplementary table 1). With the exception of a difference in the mean age in the validation cohorts in which the controls were younger on average than cases, no differences were observed between cases and controls in either the discovery or validation cohorts. PERMANOVA and sPLSDA multivariate analyses revealed significant differentiation between the microbial composition of AS cases and healthy controls for both the discovery ($p=0.019$) and validation ($p=0.0006$) cohorts (figure 1A), consistent with previous reports. Receiver-operator curve analysis showed high discrimination between cases and controls using microbiome data alone (area under curve (AUC)=0.87 in combined discovery and validation cohorts) (online supplementary figure 1).

Seven bacterial species were identified to be differentially abundant ($p < 0.05$) (ie, were 'indicator species') between AS cases and healthy controls, in both the discovery and validation

Figure 1 Taxonomic and functional dysbiosis observed in AS cases relative to healthy controls. (A) Alpha and beta diversity analysis. sPLSDA and PERMANOVA revealed community-level differences in taxonomic composition. (B) Commonly differentiated bacterial species from the discovery and validation cohorts. For visualisation purposes, data from the discovery and validation cohorts were combined. (C) Commonly differentiated KEGG Orthogroups from the discovery and validation cohorts. For visualisation purposes, data from the discovery and validation cohorts were combined. Bacterial species and KEGG Orthogroups exhibiting significant results according to multivariate linear modelling and Wilcoxon rank-sum tests are shown. AS, ankylosing spondylitis.

cohorts (figure 1B). *Clostridiales bacterium 1 7 47FAA*, *Clostridium bolteae* and *Clostridium hatheway* were found to be enriched in AS cases, while *Bifidobacterium adolescentis*, *Coprococcus comes*, *Lachnospiraceae bacterium 5 1 63FAA* and *Roseburia inulinivorans* were depleted. Several other differentially abundant species of interest were identified in either the discovery or validation cohort, notably *Prevotella copri*, *Dialister invisus* and *Faecalibacterium prausnitzii*. A full list of differentially abundant taxa in either cohort is available in the online supplementary table 2.

Six KO were also found to be differentially abundant ($p < 0.05$) in both cohorts (figure 1C), however, there were no MetaCyc metabolic pathways which were differentially abundant in both cohorts. The commonly differentiated KO were EC 2.6.1.9: histidinol-phosphate transaminase, EC 2.7.4.1: polyphosphate kinase, EC 4.3.3.6: pyridoxal 5'-phosphate synthase, EC 1.15.1.1: superoxide proteinase, EC 3.4.21.53: ATP-dependent serine phosphatase and EC 2.4.2.17: ATP phosphoribosyltransferase. Full lists of the differentially abundant KO and MetaCyc metabolic pathways are available in the online supplementary tables 3 and 4, respectively. All indicator species, except for *Lachnospiraceae bacterium 5 1 63FAA*, were significantly associated ($p < 0.05$) with the KO, however, the degree of variation explained by these species was typically low with R^2 values ranging from 0.0008 to 0.13 (0.043 on average) (online supplementary table 5).

Strain-level profiling of the dysbiotic microbes identified in figure 1B uncovered no differences in strain composition between AS cases and healthy controls (online supplementary figure 2). This suggests that gut dysbiosis may primarily be a result of differential abundance at the species level and that functional or metabolic differences in the microbiome occur from common genetic elements among the strain population, as evidenced by KO being detectable in the majority of samples in figure 1C.

Effect of TNFi therapy upon the microbiome

To test the effect of TNFi therapy on the gut microbiome, the discovery and validation cohorts were combined to enable sufficient sample sizes for the following categories: healthy controls ($n=123$), AS cases treated with TNFi (either etanercept or infliximab, $n=67$) and AS cases who have not received TNFi treatment ($n=60$). No statistically significant effect of sulfasalazine treatment was observed ($p=0.76$, online supplementary figure 3), possibly due to sample size constraints. Multivariate comparison of TNFi untreated and treated cases revealed an effect of TNFi treatment on the overall composition of the microbiome ($p=0.022$) (figure 2A). Untreated cases were significantly different to healthy controls ($p=0.0002$), whereas treated cases were not significantly different to healthy controls ($p=0.069$), highlighting a correlation between treatment and restoration of the perturbed composition of the microbiome.

To identify the key species modulated by the effects of TNFi therapy, species which were both (a) perturbed in untreated AS cases relative to healthy controls, and (b) differently abundant in treated cases compared with untreated cases, were first identified (figure 2B, supplementary table 6). Six of the eight identified species exhibited significant depletion in untreated AS cases, however, TNFi treatment was correlated with restoration of these species to levels indistinguishable from healthy controls. These species were: *P. copri*, *F. prausnitzii*, *Bilophila unclassified*, *Klebsiella pneumoniae*, *Ruminococcus bromii* and *Eubacterium bifforme*. The remaining two species (*Clostridium symbiosum*

and *Eggerthella unclassified*) were enriched in untreated AS and their abundance was no longer different to healthy controls in treated cases. The findings in relation to *P. copri* and *K. pneumoniae* were of particular interest given their previous association with rheumatoid arthritis (RA) and AS, respectively, as was the highly abundant (approximately 20% of total bacterial DNA, on average) *F. prausnitzii* for its notable depletion in several autoimmune diseases.²⁸ TNFi therapy appeared to partially normalise the dysbiotic bacterial species and KO observed in AS cases relative to healthy controls shown in figure 1B and C, however no statistically significant differences between treated and untreated cases were observed, potentially due to sample size constraints (online supplementary figure 4).

The above approach was also used to identify metabolic pathways modulated by TNFi therapy. Twenty MetaCyc metabolic pathways were identified in total and the perturbed abundance observed in untreated AS cases was restored to healthy control levels in 17 of these. In broad terms, these pathways primarily related to amino acid biosynthesis (notably branched-chain and aromatic amino acid biosynthesis), carbohydrate metabolism (notably starch degradation), nucleotide biosynthesis, metabolite biosynthesis and cell structure. Specific details of the 20 differentially abundant MetaCyc pathways are available in the online supplementary table 7.

Linear regression was used to investigate the association between the modulated species and modulated pathways (online supplementary table 8). Except for PWY-6545, pyrimidine biosynthesis which was not associated with any individual identified species, all the pathways were significantly associated with at least two of the identified species. Similarly, all the species were significantly associated with multiple pathways, however the abundances of *Bilophila unclassified* and *K. pneumoniae* were inversely correlated with pathway abundance. An increase in *K. pneumoniae* was associated with a decrease in the abundance of PWY-6737: starch degradation ($p=0.014$; $R^2=-0.043$). The observed decrease in the starch degradation pathway for untreated AS cases is primarily attributed to a depletion of *F. prausnitzii* ($p=2.38 \times 10^{-24}$; $R^2=0.31$). *Faecalibacterium prausnitzii* also exhibited strong associations with other metabolic pathways.

Strain-level profiling of the bacterial species outlined in figure 2B also revealed no discernible differences in strain composition between healthy controls, treated cases and untreated cases, indicating the TNFi therapy was associated with changes in the relative abundance of each species, not necessarily the underlying strain composition (online supplementary figure 5).

Bacterial-derived HLA-B27 epitopes in AS cases and healthy controls

To investigate the potential effects of HLA-B27 to 'shape' the gut microbiome, we assessed the abundance of bacterial peptides homologous to HLA-B27 epitopes in AS cases and healthy controls. Translated nucleotide searches were performed against IEBD v3.0, annotated according to a published study¹⁵ and counted. Significant enrichment of these peptide sequences was observed in AS cases, with 24 of these enriched in both the discovery and validation cohorts (online supplementary table 9). AS cases not only exhibited enrichment of these peptides but the overall diversity of peptides was also increased, with Shannon, Inverse Simpson and Chao diversity indices revealing significant differences between AS cases and healthy controls (figure 3A).

Figure 2 Effect of TNFi therapy on the microbiome. (A) Alpha and beta diversity analysis. sPLSDA and PERMANOVA revealed community-level differences in taxonomic composition. (B) Bacterial species modulated by the effects of TNFi treatment. Bacterial species exhibiting significant results according to multivariate linear modelling and Wilcoxon rank-sum tests are shown. TNFi, tumour necrosis factor-inhibitor.

Figure 3 (A) Enrichment, both in terms of abundance and diversity, of bacterial peptides homologous to HLA-B27 epitopes in cases relative to healthy controls. (B) Differential abundance and diversity of bacterial peptides homologous to HLA-B27 epitopes in TNFi-treated and TNFi-untreated cases and healthy controls. HC, healthy control; TNFi, tumour necrosis factor-inhibitor.

The overall abundance and diversity of bacterial peptides homologous to HLA-B27-presented epitopes were also significantly different between different TNFi treatment categories (figure 3B). Untreated AS cases exhibited increased abundance and diversity of peptides. For patients who underwent TNFi therapy, a reduction in these peptides was observed relative to untreated cases, however their levels remained marginally higher than healthy controls.

T-cell responses to HLA-B27-presenting bacterial peptides

In a preliminary study, CD8 responses to peptides known to be presented by HLA-B27 and found in the AS case stool microbiomes were assessed in two lines from different patients. CD8 responses as assessed by IFN- γ production were observed in the HLA-B27-positive donor to multiple peptides (figure 4). No such responses were noted in the HLA-B27-negative donor (figure 4).

Figure 4 CD8 T-cell responses to peptide stimulation. Intracellular interferon- γ responses are reported for synthetic peptides listed in the online supplementary table 9. Data are presented for PBMCs alone with no peptide addition ('T-cell only'), PBMCs with LCLs added at day 10–14 with no peptide addition ('APC only'), and with both LCL and peptide addition (other lanes). Open columns refer to findings from an HLA-B*2704/B*4006 AS case, hatched columns refer to findings from an HLA-B*1502/B*4001 healthy control. Panels A and B represent separate experiments with different peptides added. APC, antigen presenting cell; IFN, interferon; LCL, lymphoblastoid cell line; PBMC, peripheral blood mononuclear cell.

DISCUSSION

Gut dysbiosis in AS

This study reconfirmed the occurrence of bacterial gut dysbiosis in AS cases and identified seven bacterial species which were commonly differentiated between cases and controls in both the discovery and validation cohorts (figure 1B). Two of these species, *Bifidobacterium adolescentis* and *Coprococcus comes*, have been noted for their depletion in Crohn disease²⁹ and were also observed to be depleted in AS cases in this study. An additional two species previously reported to be associated with AS, *P. copri* and *D. invisus*, were found to be differentially abundant in either the discovery or validation cohorts (online supplementary table 2). In the case of *P. copri*, previous studies have demonstrated enrichment in new-onset RA cases yet depletion in chronic RA cases.³⁰ Consistent with these findings, our study found that *P. copri* was depleted in AS cases within the non-age-matched cohort, for which the demographics were heavily skewed towards older patients with AS with the long-standing disease (online supplementary table 1). Previous studies in AS have shown increases in *Prevotellaceae*¹⁰ or specifically with this species.¹¹ As discussed below, *P. copri* carriage normalised with TNFi treatment. Further studies will be required to determine if *P. copri* carriage changes with disease duration, as has been reported in RA.

Carriage of *Dialister* species has been previously associated with disease activity in patients with SpA,¹³ but the carriage of *D. invisus* has been reported to be decreased in IBD.^{31 32} While we found enrichment of *D. invisus* in AS cases in the discovery cohort, this was not confirmed in the validation cohort, nor has it been reported in other AS studies. Its pathogenic significance is therefore uncertain.

Of particular interest, the notable 'peace keeping' microbe *F. prausnitzii* was also found to be depleted in AS cases in the validation cohort. This bacterium has also been consistently shown to be depleted in IBD^{32–37} and has been previously shown to be depleted in the disease enthesitis-related arthritis, a paediatric disease-classification which includes children with AS.³⁸ *Faecalibacterium prausnitzii* is known to produce butyrate and other metabolites and peptides that have diverse anti-inflammatory

effects including promoting T-regulatory cell differentiation,³⁹ influences on Th17 lymphocyte activation and promotion of gut mucosal barrier function.^{37 40 41} As discussed below, TNFi treatment also led to normalisation of *F. prausnitzii* carriage. These findings suggest that *F. prausnitzii* plays a key anti-inflammatory role in AS, as it does in IBD.

Using metagenome sequencing to provide a functional characterisation of the microbiome, this study shows that genes encoding pyridoxal 5'-phosphate synthase, an important enzyme for the biosynthesis of vitamin B6, were less abundant among the microbiome of AS cases compared with healthy controls in both cohorts. Vitamin B6 plays a role in the maintenance of vitamin homeostasis in colonocytes.^{42 43} It has been found to modulate colonic inflammation and several studies that have investigated the role of vitamin B6 for the treatment of inflammation in patients with RA.^{44–49} Evidence from case-control studies show that patients with RA have low vitamin B6 status compared with healthy controls, however, intervention studies have yielded inconsistent findings, possibly due to the dose of the administered vitamin B6. The reduced potential for the microbiome of patients with AS to produce pyridoxal 5'-phosphate synthase, and thus vitamin B6, may warrant further investigation into intervention strategies to mitigate inflammation in patients with AS.

MetaCyc pathway analysis revealed the depletion of the aromatic and branched-chain amino acid biosynthesis pathways in untreated AS cases, which are responsible for the production of four of the nine essential amino acids in humans (leucine, isoleucine, valine and phenylalanine) (online supplementary table 7). Vitamin B6 is an essential cofactor for branched-chain amino acid transaminase, the last step of the branched-chain amino acid synthesis. Therefore, in the current study, we not only observed depletion of genes encoding the branched-chain amino acid biosynthesis pathway but also for the enzyme which synthesises an important cofactor in the process.

Effect of TNFi therapy upon the microbiome

The previous study of patients with RA before and after synthetic disease-modifying antirheumatic drug treatment revealed moderate differences in the gut microbiota composition, with the perturbed microbial composition being partly restored following treatment.⁵⁰ Similarly, analysis of patients with SpA before and after TNFi therapy also revealed modest differences in microbial composition yet no specific taxon was found to be modulated, likely due to sample size.¹⁴ Using a larger sample size, we confirmed that TNFi therapy was correlated with a restoration of the perturbed microbial composition, and additionally identified several notable bacterial species modulated by treatment.

We observed that TNFi therapy restored the depletion of *F. prausnitzii* in AS cases. Restoration of *F. prausnitzii* abundance was also correlated with the restored abundance of aromatic and branched-chain amino acid biosynthesis pathways. A recent ulcerative colitis study³³ revealed reduced dysbiosis and increased *F. prausnitzii* abundance in responders compared with non-responders following TNFi therapy. Furthermore, recovery of *F. prausnitzii* in patients with ulcerative colitis after relapse was associated with maintenance of remission.⁵¹ Another study demonstrated that treatment of infliximab completely restored *F. prausnitzii* concentrations from zero to 1.4×10^{10} bacteria/mL within a few days.³⁰

Another important microbe, *P. copri*, was observed to be enriched to levels closely matched to that of healthy controls following TNFi treatment. The abundance of *P. copri* has

previously been shown to be enriched in patients with untreated new-onset RA yet depleted in chronic RA cases, patients with psoriatic arthritis and healthy controls.³⁰ Colonisation of SKG mice with *P. copri*-dominated microbiota from patients with RA led to an increased number of Th17 cells in the large intestine.⁵² HLA-DR-presented peptides (T-cell epitopes) from *P. copri* were recently found to stimulate Th1 responses in 42% of new-onset RA cases, with subgroups of patients with RA demonstrating differential IgG or IgA immune reactivity, providing evidence that *P. copri* is immune-relevant in RA pathogenesis.⁵³ Additionally, the presence of the *HLA-DRB1* risk allele, which influences disease severity, in patients with RA was found to be inversely correlated with *P. copri* abundance.^{30 54–56} A recent study of Chinese patients with AS revealed enrichment of *P. copri*, as well as *P. melaninogenica* and *Prevotella* sp. C561.¹¹ Contrasting these results, in the current study, we observed a depletion of *P. copri* in untreated AS cases, which was restored to the healthy control levels in TNFi-treated patients. These seemingly conflicting reports of *P. copri* abundance may be explained by the large degree of intraspecific genetic diversity of *P. copri* strains, with strain variation adding an additional layer of complexity for predicting the function of *P. copri* in the gut. The *Prevotella* genus also contains members that may be beneficial, and which do not function as pathobionts,^{54–56} with observed enrichment in healthy individuals. Taken together, our results which demonstrate modulation of *P. copri* abundance in TNFi-treated cases are a noteworthy observation, however without a stronger grasp of the strain-level genome variation within this taxon and their prevalence across our cohort attempts to therapeutically modulate and predict the effects of *P. copri* remain significant challenges.⁵⁷

Klebsiella pneumoniae has also been suggested to play a significant role in AS pathogenesis,⁵⁸ although this remains controversial.⁵⁹ *Klebsiella pneumoniae* notably produces pullulanase, a starch-debranching enzyme which enables the degradation of starch into simple sugars.⁶⁰ The apparent arthritogenic effects of dietary starch in AS are based on the concept that the growth of *Klebsiella* sp. are favoured by these diets and drive AS pathogenesis.^{61 62} Consequently, low starch diets have been promoted and are frequently followed by patients,⁶² although there is no published evidence to date as to their efficacy in positively affecting AS disease course. Here, we actually observed depletion of this microbe in untreated cases relative to healthy controls, whereas TNFi-treated cases showed a restoration of this bacterium. Furthermore, our metagenome sequencing data showed an inverse correlation between *K. pneumoniae* relative abundance and the overall starch degradation metabolic pathway ($p=0.014$; $R^2=-0.043$) (online supplementary table 5). This pathway not only includes the pullulanase-mediated starch debranching reaction but also further downstream reactions including the transport and catabolism of maltodextrins. These findings do not support an association between *K. pneumoniae* and AS pathophysiology, although the role of dietary and/or resistant starches on the gut microbiota and AS warrants further investigation.

Enrichment of bacterial peptides

Pathogenic bacteria have long been hypothesised as an immunological trigger of AS pathogenesis. In the current study, patients with AS not only demonstrated enrichment of bacterial peptides matching HLA-B27 epitopes (online supplementary table 9), but the diversity of these peptides was greater overall (figure 3A). These data provide supporting evidence for the molecular mimicry hypothesis for which bacterial-derived peptides may

stimulate AS via cross-activation of autoreactive T cells or B cells, thus leading to autoimmunity. Only limited evidence of CD8 T-cell reactivity to specific antigens has previously been reported in AS⁶³ or the related disease reactive arthritis.⁶⁴ In our preliminary studies, we showed substantial responses of CD8 T cells to peptides known to be presentable by HLA-B27, and were also found in the stool microbiome of AS cases, in HLA-B27-positive but not HLA-B27-negative donors. Considerable further studies are indicated to investigate this in greater detail including the range of peptides involved, extent of HLA-restriction and differences in T-cell reactivity between AS cases and healthy controls. This hypothesis does not however explain the increase in HLA-B27 epitopes among AS cases, which could be explained by effects of non-HLA genetic factors or AS-associated environmental factors. An alternate hypothesis is that their excess carriage is caused by a deficiency in the ability of HLA-B27 to effectively control their presence, consistent with evidence of increased bacterial migration across the gut mucosa in AS.⁶⁵ Interestingly, the modulation of the gut microbiome associated with TNFi treatment was also associated with a restoration of the elevated abundance and diversity of peptides observed in untreated cases to levels which were more closely matched to healthy controls (figure 3B). Further research will be required to resolve these alternate hypotheses.

Limitations

Given the known heterogeneity of the gut microbiome in different geographical locations, changes in specific bacterial species may not be replicable in other populations. Furthermore, known technical variability also limits the direct comparison of results between different sequencing methodologies and bioinformatic approaches. A meta-analysis of metagenomics data from diverse populations which have undergone identical data processing procedures will be required in the future to counteract known technical and biological biases. Larger sample sizes may also be required to provide sufficient statistical power, for example, to examine the effect of sulfasalazine on the microbiome. Further work is also required to establish causal relationships between the identified associations. Given the large number of peptides presented by HLA-B27, it is likely that many more peptides other than the ones identified in this study are enriched in the microbiome of patients with AS. Larger sample sizes and continual update of the Immune Epitope Database are likely to expand on our initial observations.

CONCLUSIONS

In summary, this study confirms that AS is characterised by gut dysbiosis and identifies key indicator species, several of which are shared with IBD. This dysbiosis is associated with functional differences in the microbiome involving known inflammation-related pathways. We demonstrate that treatment with TNFi, which is highly effective in suppressing the clinical manifestations of AS, is correlated with normalisation of the gut microbiome, and its functional properties, in AS cases. We further demonstrate that the AS gut microbiome is enriched for bacterial peptides that have previously been shown to be presented by HLA-B27 and that this enrichment is also normalised by TNFi treatment. These findings are consistent with disease models in which AS pathogenesis is driven by interactions between a genetically primed host immune system, and the gut microbiome and point to potential therapeutic and/or preventative approaches for the disease.

Author affiliations

- ¹Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, China
- ²Translational Genomics Group, Institute of Health and Biomedical Innovation, Brisbane, Queensland, Australia
- ³Shanghai Key Laboratory of Birth Defects, Children's Hospital of Fudan University, Shanghai, China
- ⁴University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
- ⁵Imunobio, Shenzhen, China
- ⁶Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China
- ⁷Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing, China

Correction notice This article has been corrected since it published Online First. The second corresponding author has been added and affiliation 7 has been updated.

Acknowledgements The authors acknowledge and thank the contribution of the subjects who participated in this study.

Contributors Study design was performed by HX, JY and MAB. Subject recruitment and sample collection was performed by JY, JS, TL, LZ, XW and JZ. Metagenomic analysis was performed by PRS, and bacterial epitope studies by JY, FH and MW. The manuscript was prepared by PRS, MM, MAB and HX.

Funding HX is supported by National Science Foundation of China (Grant 81430031) and China Ministry of Science and technology (973 Program of China 2014CB541800). MAB is funded by a National Health and Medical Research Council Senior Principal Research Fellowship (#1024879).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval All human studies have been approved by the Research Ethical Committee of Second Military Medical University, and all patients and controls gave informed written consent for their participation in the studies.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

ORCID iDs

Mingbang Wang <http://orcid.org/0000-0002-5989-5377>

Jian Zhu <http://orcid.org/0000-0002-6244-9917>

Matthew A Brown <http://orcid.org/0000-0003-0538-8211>

REFERENCES

- 1 Pedersen OB, Svendsen AJ, Ejstrup L, *et al.* Ankylosing spondylitis in Danish and Norwegian twins: occurrence and the relative importance of genetic vs. environmental effectors in disease causation. *Scand J Rheumatol* 2008;37:120–6.
- 2 Brown MA, Kennedy LG, MacGregor AJ, *et al.* Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. *Arthritis Rheum* 1997;40:1823–8.
- 3 Mielants H, Veys EM, Cuvelier C, *et al.* The evolution of spondyloarthropathies in relation to gut histology. II. histological aspects. *J Rheumatol* 1995;22:2273–8.
- 4 Ellinghaus D, Jostins L, Spain SL, *et al.* Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. *Nat Genet* 2016;48:510–8.
- 5 Thjodleifsson B, Geirsson Ární J, Björnsson S, *et al.* A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogical study in Iceland. *Arthritis Rheum* 2007;56:2633–9.
- 6 Parkes M, Cortes A, van Heel DA, *et al.* Genetic insights into common pathways and complex relationships among immune-mediated diseases. *Nat Rev Genet* 2013;14:661–73.
- 7 Li Z, Haynes K, Pennisi DJ, *et al.* Epigenetic and gene expression analysis of ankylosing spondylitis-associated loci implicate immune cells and the gut in the disease pathogenesis. *Genes Immun* 2017;18:135–43.
- 8 Taurug JD, Richardson JA, Croft JT, *et al.* The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. *J Exp Med* 1994;180:2359–64.
- 9 Rehaume LM, Mondot S, Aguirre de Cárcer D, *et al.* Zap-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice. *Arthritis Rheumatol* 2014;66:2780–92.
- 10 Costello M-E, Ciccia F, Willner D, *et al.* Brief report: intestinal dysbiosis in ankylosing spondylitis. *Arthritis Rheumatol* 2015;67:686–91.
- 11 Wen C, Zheng Z, Shao T, *et al.* Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis. *Genome Biol* 2017;18:142.
- 12 Asquith M, Sternes PR, Costello Mary-ellen, *et al.* HLA Alleles Associated With Risk of Ankylosing Spondylitis and Rheumatoid Arthritis Influence the Gut Microbiome. *Arthritis Rheumatol* 2019;71:1642–50.

- 13 Tito RY, Cypers H, Joossens M, *et al.* Brief Report: *Dialister* as a Microbial Marker of Disease Activity in Spondyloarthritis. *Arthritis Rheumatol* 2017;69:114–21.
- 14 Bazin T, Hooks KB, Barnette T, *et al.* Microbiota composition may predict anti-TNF alpha response in spondyloarthritis patients: an exploratory study. *Sci Rep* 2018;8:5446.
- 15 Schittenhelm RB, Sian TCCLK, Wilmann PG, *et al.* Revisiting the arthritogenic peptide theory: quantitative not qualitative changes in the peptide repertoire of HLA-B27 allotypes. *Arthritis Rheumatol* 2015;67:702–13.
- 16 Linden SVD, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. *Arthritis Rheumatism* 1984;27:361–8.
- 17 Andrews S. FastQC: a quality control tool for high throughput sequence data 2010.
- 18 Zhang J, Kobert K, Flouri T, *et al.* Pear: a fast and accurate Illumina Paired-End reAd merger. *Bioinformatics* 2014;30:614–20.
- 19 Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 2014;30:2114–20.
- 20 Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 2012;9:357–9.
- 21 Li H. seqtk toolkit for processing sequences in FASTA/Q formats. *GitHub* 2012.
- 22 Truong DT, Franzosa EA, Tickle TL, *et al.* MetaPhlAn2 for enhanced metagenomic taxonomic profiling. *Nat Methods* 2015;12:902–3.
- 23 Scholz M, Ward DV, Pasoli E, *et al.* Strain-level microbial epidemiology and population genomics from shotgun metagenomics. *Nat Methods* 2016;13:435–8.
- 24 Abubucker S, Segata N, Goll J, *et al.* Metabolic reconstruction for metagenomic data and its application to the human microbiome. *PLoS Comput Biol* 2012;8:e1002358.
- 25 Altschul SF, Gish W, Miller W, *et al.* Basic local alignment search tool. *J Mol Biol* 1990;215:403–10.
- 26 Vita R, Overton JA, Greenbaum JA, *et al.* The immune epitope database (IEDB) 3.0. *Nucleic Acids Res* 2015;43:D405–12.
- 27 Kim Y, Ponomarenko J, Zhu Z, *et al.* Immune epitope database analysis resource. *Nucleic Acids Res* 2012;40:W525–30.
- 28 Forbes JD, Van Domselaar G, Bernstein CN. The gut microbiota in immune-mediated inflammatory diseases. *Front Microbiol* 2016;7:1081.
- 29 Gevers D, Kugathasan S, Denson LA, *et al.* The treatment-naïve microbiome in new-onset Crohn's disease. *Cell Host Microbe* 2014;15:382–92.
- 30 Scher JU, Sczesnak A, Longman RS, *et al.* Expansion of intestinal *Prevotella copri* correlates with enhanced susceptibility to arthritis. *eLife* 2013;2.
- 31 Joossens M, Huys G, Cnockaert M, *et al.* Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut* 2011;60:631–7.
- 32 Schirmer M, Franzosa EA, Lloyd-Price J, *et al.* Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. *Nat Microbiol* 2018;3:337–46.
- 33 Magnusson MK, Strid H, Sapnara M, *et al.* Anti-Tnf therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. *J Crohns Colitis* 2016;10:943–52.
- 34 Preter DV, Machiels K, Joossens M, *et al.* Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. *Gut* 2014.
- 35 Le Gall Gwénaëlle, Noor SO, Ridgway K, *et al.* Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. *J Proteome Res* 2011;10:4208–18.
- 36 Marchesi JR, Holmes E, Khan F, *et al.* Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. *J Proteome Res* 2007;6:546–51.
- 37 Machiels K, Joossens M, Sabino J, *et al.* A decrease of the butyrate-producing species *Roseburia hominis* and *Faecalibacterium prausnitzii* defines dysbiosis in patients with ulcerative colitis. *Gut* 2014;63:1275–83.
- 38 Stoll ML, Kumar R, Morrow CD, *et al.* Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. *Arthritis Res Ther* 2014;16.
- 39 Arpaia N, Campbell C, Fan X, *et al.* Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 2013;504:451–5.
- 40 Sokol H, Pigneur B, Watterlot L, *et al.* *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A* 2008;105:16731–6.
- 41 Neis E, Dejong C, Rensen S. The role of microbial amino acid metabolism in host metabolism. *Nutrients* 2015;7:2930–46.
- 42 Rucker RB, Suttie JW, McCormick DB. *Handbook of vitamins*. CRC Press, 2001.
- 43 Magnúsdóttir S, Ravcheev D, de Crécy-Lagard V, *et al.* Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. *Front Genet* 2015;6:148.
- 44 Woolf K, Manore MM. Elevated plasma homocysteine and low vitamin B-6 status in nonsupplementing older women with rheumatoid arthritis. *J Am Diet Assoc* 2008;108:443–53.
- 45 Schumacher HR, Bernhart FW, György P. Vitamin B6 levels in rheumatoid arthritis: effect of treatment. *Am J Clin Nutr* 1975;28:1200–3.
- 46 Chiang E-PI, Bagley PJ, Selhub J, *et al.* Abnormal vitamin B6 status is associated with severity of symptoms in patients with rheumatoid arthritis. *Am J Med* 2003;114:283–7.
- 47 Chiang E-PI, Selhub J, Bagley PJ, *et al.* Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis. *Arthritis Res Ther* 2005;7.
- 48 O'Connor Á. An overview of the role of diet in the treatment of rheumatoid arthritis. *Nutrition Bulletin* 2014;39:74–88.
- 49 Selhub J, Byun A, Liu Z, *et al.* Dietary vitamin B6 intake modulates colonic inflammation in the IL10–/– model of inflammatory bowel disease. *J Nutr Biochem* 2013;24:2138–43.
- 50 Zhang X, Zhang D, Jia H, *et al.* The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. *Nat Med* 2015;21:895–905.
- 51 Varela E, Manichanh C, Gallart M, *et al.* Colonisation by *Faecalibacterium prausnitzii* and maintenance of clinical remission in patients with ulcerative colitis. *Aliment Pharmacol Ther* 2013;38:151–61.
- 52 Maeda Y, Kurakawa T, Umemoto E, *et al.* Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. *Arthritis Rheumatol* 2016;68:2646–61.
- 53 Pianta A, Arvikar S, Strle K, *et al.* Evidence of the Immune Relevance of *Prevotella copri*, a Gut Microbe, in Patients With Rheumatoid Arthritis. *Arthritis Rheumatol* 2017;69:964–75.
- 54 Glick-Bauer M, Yeh M-C. The health advantage of a vegan diet: exploring the gut microbiota connection. *Nutrients* 2014;6:4822–38.
- 55 Kovatcheva-Datchary P, Nilsson A, Akrami R, *et al.* Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of *Prevotella*. *Cell Metab* 2015;22:971–82.
- 56 Kim D, Kim W-U. Editorial: Can *Prevotella copri* Be a Causative Pathobiont in Rheumatoid Arthritis? *Arthritis Rheumatol* 2016;68:2565–7.
- 57 Ley RE. Gut microbiota in 2015: *Prevotella* in the gut: choose carefully. *Nat Rev Gastroenterol Hepatol* 2016;13:69–70.
- 58 Ebringer R, Cooke D, Cawdell DR, *et al.* Ankylosing spondylitis: *Klebsiella* and HLA-B27. *Rheumatology* 1977;16:190–6.
- 59 Stone MA, Payne U, Schentag C. Comparative immune responses to candidate arthritogenic bacteria do not confirm a dominant role for *Klebsiella pneumoniae* in the pathogenesis of familial ankylosing spondylitis. *Rheumatology* 2003;43:148–55.
- 60 Pugsley AP, Chapon C, Schwartz M. Extracellular pullulanase of *Klebsiella pneumoniae* is a lipoprotein. *J Bacteriol* 1986;166:1083–8.
- 61 Ebringer A, Wilson C. The use of a low starch diet in the treatment of patients suffering from ankylosing spondylitis. *Clin Rheumatol* 1996;15:62–6.
- 62 Rashid T, Wilson C, Ebringer A. The Link between Ankylosing Spondylitis, Crohn's Disease, *Klebsiella*, and Starch Consumption. *Clin Develop Immunol* 2013;2013:1–9.
- 63 Fiorillo MT, Maragno M, Butler R, *et al.* CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. *J Clin Invest* 2000;106:47–53.
- 64 Hermann E, Meyer zum Büschenfelde K-H, Fleischer B, *et al.* HLA-B27-Restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. *The Lancet* 1993;342:646–50.
- 65 Ciccia F, Guggino G, Rizzo A, *et al.* Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. *Ann Rheum Dis* 2017;76:1123–32.